 San Diego, Calif, Jan. 15, 2021 GLOBE NEWSWIRE -- Emerald Bioscience, Inc. OTCQB: EMBI EMBI or the Company, a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc. The Company will trade under its new ticker symbol, SKYE, on the OTC effective at market open on Tuesday, January 19, 2021. 